Genetic predictors of medically refractory ulcerative colitis

Inflammatory Bowel Diseases

Volumn 16, Issue 11, 2010, Pages 1830-1840

  Haritunians, Talin ^a   Taylor, Kent D ^a   Targan, Stephan R ^a   Dubinsky, Marla ^a   Ippoliti, Andrew ^a   Kwon, Soonil ^a   Guo, Xiuqing ^a   Melmed, Gil Y ^a   Berel, Dror ^a   Mengesha, Emebet ^a   Psaty, Bruce M ^b   Glazer, Nicole L ^b   Vasiliauskas, Eric A ^a   Rotter, Jerome I ^a   Fleshner, Phillip R ^a   McGovern, Dermot P B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

genetics; natural history; ulcerative colitis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; COHORT ANALYSIS; COLON RESECTION; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; FAMILY HISTORY; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENETICS; GENOME; HAZARD; HEREDITY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; ULCERATIVE COLITIS;

ACUTE DISEASE; ADOLESCENT; ADULT; COHORT STUDIES; COLECTOMY; COLITIS, ULCERATIVE; FEMALE; GENETIC LOCI; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; YOUNG ADULT;

EID: 78249287838     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21293     Document Type: Article

References (71)

1. Franke A, Balschun T, Karlsen TH, et al. Replication of signals from recent studies of Crohns disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet. 2008; 40: 713-715.
2. Fisher SA, Tremelling M, Anderson CA, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohns disease. Nat Genet. 2008; 40: 710-712.
3. Franke A, Balschun T, Karlsen TH, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008; 40: 1319-1323.
4. Silverberg MS, Cho JH, Rioux JD, et al. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found by genome-wide association study. Nat Genet. 2009; 41: 216-220.
5. Anderson CA, Massey DC, Barrett JC, et al. Investigation of Crohns disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology. 2009; 136: 523-529.
6. Asano K, Matsushita T, Umeno J, et al. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population. Nat Genet. 2009; 41: 1325-1329.
7. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohns disease. Nat Genet. 2008; 40: 955-962.
8. Farmer RG, Easley KA, Rankin GB,. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993; 38: 1137-1146.
9. Henriksen M, Jahnsen J, Lygren I, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis. 2006; 12: 543-550.
10. Hendriksen C, Kreiner S, Binder V,. Long term prognosis in ulcerative colitis-based on results from a regional patient group from the county of Copenhagen. Gut. 1985; 26: 158-163.
11. Fraga XF, Vergara M, Medina C, et al. Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1997; 9: 683-687.
12. Mokbel M, Carbonnel F, Beaugerie L, et al. [Effect of smoking on the long-term course of ulcerative colitis.] Gastroenterol Clin Biol. 1998; 22: 858-862.
13. Basu D, Lopez I, Kulkarni A, et al. Impact of race and ethnicity on inflammatory bowel disease. Am J Gastroenterol. 2005; 100: 2254-2261.
14. Nguyen GC, Torres EA, Regueiro M, et al. Inflammatory bowel disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort. Am J Gastroenterol. 2006; 101: 1012-1023.
15. Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology. 1997; 112: 1845-1853.
16. Bouma G, Crusius JB, Garcia-Gonzalez MA, et al. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol. 1999; 115: 294-300.
17. de la Concha EG, Fernandez-Arquero M, Lopez-Nava G, et al. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. Gastroenterology. 2000; 119: 1491-1495.
18. Yamamoto-Furusho JK, Uscanga LF, Vargas-Alarcon G, et al. Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. Hum Immunol. 2003; 64: 119-123.
19. Ahmad T, Armuzzi A, Neville M, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens. 2003; 62: 527-535.
20. Fernandez L, Nunez C, Mendoza JL, et al. A recombined haplotype in the major histocompatibility region contains a cluster of genes conferring high susceptibility to ulcerative colitis in the Spanish population. Inflamm Bowel Dis. 2005; 11: 785-791.
21. Brant SR, Panhuysen CI, Nicolae D, et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet. 2003; 73: 1282-1292.
22. Ho GT, Gaya DR, Satsangi J,. Multidrug resistance (MDR1) gene in inflammatory bowel disease: a key player? Inflamm Bowel Dis. 2005; 11: 1013-1019.
23. Ho GT, Soranzo N, Nimmo ER, et al. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet. 2006; 15: 797-805.
24. Weedon MN, McCarthy MI, Hitman G, et al. Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med. 2006; 3: e374.
25. Lu Q, Elston RC,. Using the optimal receiver operating characteristic curve to design a predictive genetic test, exemplified with type 2 diabetes. Am J Hum Genet. 2008; 82: 641-651.
26. Evans DM, Visscher PM, Wray NR,. Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk. Hum Mol Genet. 2009; 18: 3525-3531.
27. Henckaerts L, Van Steen K, Verstreken I, et al. Genetic risk profiling and prediction of disease course in Crohns disease patients. Clin Gastroenterol Hepatol. 2009; 7: 972-980 e2.
28. Dubinsky M, Ling M, Friedman, M, et al. Genome wide association (GWA) predictors of anti-TNFf? therapeutic responsiveness in pediatric inflammatory bowel disease (IBD). Inflamm Bowel Dis. 2010 [Epub ahead of print] doi:10.1002/ibd.21174.
29. Lennard-Jones JE, Ritchie JK, Zohrab WJ,. Proctocolitis and Crohns disease of the colon: a comparison of the clinical course. Gut. 1976; 17: 477-482.
30. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1: 263-276.
31. Psaty BM, O'Donnell CJ, Gudnason V, et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet. 2009; 2: 73-80.
32. Gunderson KL, Steemers FJ, Ren H, et al. Whole-genome genotyping. Methods Enzymol. 2006; 410: 359-376.
33. Gunderson KL, Steemers FJ, Lee G, et al. A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet. 2005; 37: 549-554.
34. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007; 81: 559-575.
35. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet. 2006; 38: 904-909.
36. Devlin B, Roeder K,. Genomic control for association studies. Biometrics. 1999; 55: 997-1004.
37. R: A language and environment for statistical computing. Version 2.9.0. Vienna, Austria; 2006.
38. Heagerty PJ, Lumley T, Pepe MS,. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000; 56: 337-344.
39. Lasko TA, Bhagwat JG, Zou KH, et al. The use of receiver operating characteristic curves in biomedical informatics. J Biomed Inform. 2005; 38: 404-415.
40. Sing T, Sander O, Beerenwinkel N, et al. ROCR: visualizing classifier performance in R. Bioinformatics. 2005; 21: 3940-3941.
41. Efron B,. Bootstrap methods: another look at the jackknife. Ann Stat. 1979; 7: 1-26.
42. Zhu H, Rohwer R,. No free lunch for cross-validation. Neural Comput. 1996; 8: 1421-1426.
43. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009; 44: 431-440.
44. Imielinski M, Baldassano RN, Griffiths A, et al. Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet. 2009; 41: 1335-1340.
45. Barrett JC, Lee JC, Lees CW, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet. 2009; 41: 1330-1334.
46. Takedatsu H, Michelsen KS, Wei B, et al. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology. 2008; 135: 552-567.
47. Hanley JA, McNeil BJ,. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143: 29-36.
48. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837-1847.
49. McGovern DPB, Summerskill WSM, McManus R, et al. Evidence-based medicine in general practice. BIOS Scientific Publishers; 2001.
50. Matanis T, Akhmanova A, Wulf P, et al. Bicaudal-D regulates COPI-independent Golgi-ER transport by recruiting the dynein-dynactin motor complex. Nat Cell Biol. 2002; 4: 986-992.
51. Moorhead AR, Rzomp KA, Scidmore MA,. The Rab6 effector bicaudal D1 associates with Chlamydia trachomatis inclusions in a biovar-specific manner. Infect Immun. 2007; 75: 781-791.
52. Ide N, Hata Y, Nishioka H, et al. Localization of membrane-associated guanylate kinase (MAGI)-1/BAI-associated protein (BAP) 1 at tight junctions of epithelial cells. Oncogene. 1999; 18: 7810-7815.
53. van Bodegraven AA, Curley CR, Hunt KA, et al. Genetic variation in myosin IXB is associated with ulcerative colitis. Gastroenterology. 2006; 131: 1768-1774.
54. McGovern DP, Taylor KD, Landers C, et al. MAGI2 genetic variation and inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 75-83.
55. Wapenaar MC, Monsuur AJ, van Bodegraven AA, et al. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. Gut. 2008; 57: 463-467.
56. Jetten AM,. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl Recept Signal. 2009; 7: e003.
57. Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008; 28: 29-39.
58. Ogawa K, Tanaka K, Ishii A, et al. A novel serum protein that is selectively produced by cytotoxic lymphocytes. J Immunol. 2001; 166: 6404-6412.
59. Kuepper M, Bratke K, Julius P, et al. Increase in killer-specific secretory protein of 37 kDa in bronchoalveolar lavage fluid of allergen-challenged patients with atopic asthma. Clin Exp Allergy. 2005; 35: 643-649.
60. Yang H, Rotter JI, Toyoda H, et al. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest. 1993; 92: 1080-1084.
61. Stokkers PC, Reitsma PH, Tytgat GN, et al. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut. 1999; 45: 395-401.
62. Yamazaki K, McGovern D, Ragoussis J, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohns disease. Hum Mol Genet. 2005; 14: 3499-3506.
63. Picornell Y, Mei L, Taylor K, et al. TNFSF15 is an ethnic-specific IBD gene. Inflamm Bowel Dis. 2007; 13: 1333-1338.
64. Tremelling M, Berzuini C, Massey D, et al. Contribution of TNFSF15 gene variants to Crohns disease susceptibility confirmed in UK population. Inflamm Bowel Dis. 2008; 14: 733-737.
65. Thiebaut R, Kotti S, Jung C, et al. TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort. Am J Gastroenterol. 2009; 104: 384-391.
66. Bamias G, Martin C 3rd, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol. 2003; 171: 4868-48674.
67. Prehn JL, Mehdizadeh S, Landers CJ, et al. Potential role for TL1A, the new TNF-family member and potent costimulator of IFN-gamma, in mucosal inflammation. Clin Immunol. 2004; 112: 66-77.
68. Zini N, Lisignoli G, Solimando L, et al. IL1-beta and TNF-alpha induce changes in the nuclear polyphosphoinositide signalling system in osteoblasts similar to that occurring in patients with rheumatoid arthritis: an immunochemical and immunocytochemical study. Histochem Cell Biol. 2003; 120: 243-250.
69. McGraw DW, Almoosa KF, Paul RJ, et al. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest. 2003; 112: 619-626.
70. Shi GP, Bryant RA, Riese R, et al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med. 2000; 191: 1177-1186.
71. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005; 21: 263-265.